Table 1.

Univariate Analysis of Clinicopathological Variables, T Lymphocytes Markers, and Disease-Free (DFS) and Overall Survival (OS).

Parameter	Total (N)	5-yr DFS %	Hazard Ratio (95% CI)	P-value1	5-yr OS %	Hazard Ratio (95% CI)	P-value
Stage
II	24	75.0%	-	0.2164	83.3%	-	0.1485
III	136	61.0%	1.70 (0.73,3.96)		68.4%	1.85 (0.79,4.29)
Lymph Node Number2
0	24	75.0%	-	0.0394	83.3%	-	0.0153
1–3	91	68.9%	1.38 (0.57,3.31)		75.7%	1.48 (0.62,3.53)
>3	45	50.0%	2.51 (1.01,6.20)		59.5%	2.81 (1.14,6.91)
Histologic Grade
Well/moderate	101	62.4%	-	0.8527	71.3%	-	0.5409
Poor/undifferentiated	59	64.4%	0.95 (0.56, 1.62)		69.5%	1.17 (0.71, 1.94)
Tumor Site
Distal	75	60.0%	-	0.3051	70.7%	-	0.3130
Proximal	85	65.9%	0.76 (0.45, 1.28)		70.6%	0.77 (0.47, 1.28)
Age
<70	106	66.0%	-	0.3969	74.5%	-	0.0271
≥70	54	57.3%	1.26 (0.74,2.13)		63.0%	1.75 (1.06,2.88)
Gender
Female	76	61.8%	-	0.7772	69.7%	-	0.6917
Male	84	64.3%	0.93 (0.56, 1.55)		71.4%	0.90 (0.55, 1.49)
FoxP3+ Intraepithelial
≤ Quartile 1	59	66.1%	0.81 (0.47, 1.39)	0.4414	74.6%	0.73 (0.43, 1.24)	0.2385
> Quartile 1	101	61.4%	-		68.3%	-
FoxP3+ Stromal
≤ Quartile 1	42	61.9%	1.15 (0.63,2.08)	0.6555	66.7%	1.10 (0.62, 1.95)	0.7512
> Quartile 1	118	63.5%	-		72.0%	-
CD3+ Intraepithelial
≤ Quartile 1	47	51.1%	1.87 (1.10,3.16)	0.0180	63.8%	1.46 (0.87,2.46)	0.1492
> Quartile 1	113	68.1%	-		73.5%	-
CD3+ Stromal
≤ Quartile 1	40	70.0%	0.67 (0.35, 1.26)	0.2096	77.5%	0.70 (0.38, 1.30)	0.2612
> Quartile 1	120	60.8%	-		68.3%	-
CD3+/Foxp3+
Intraepithelial1
≤ Quartile 1	26	46.2%	2.17 (1.11,4.23)	0.0205	61.5%	1.76 (0.92,3.37)	0.0868
> Quartile 1	75	66.7%	-		70.7%	-
CD3+/Foxp3+ Stromal2
≤ Quartile 1	38	68.4%	0.78 (0.41, 1.47)	0.4406	73.7%	0.99 (0.55, 1.77)	0.9664
> Quartile 1	117	61.5%	-		69.2%	-

¹CD3⁺/Foxp3⁺ ratio for 101 patients with Foxp3⁺ TILs in tumor epithelium (i.e. counts > 0)

²CD3⁺/Foxp3⁺ ratio for 155 patients with Foxp3⁺ TILs in tumor stroma (i.e. counts > 0)